Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Volume:2 Issue:8 Number:21 ISSN#:2563-5476
Author Verified
ACE Report #4450
Ace Report Cover Arthroplasty

New oral anticoagulants do not differ significantly in safety and efficacy from enoxaparin

How to Cite

OrthoEvidence. New oral anticoagulants do not differ significantly in safety and efficacy from enoxaparin. ACE Report. 2013;2(8):21. Available from: https://myorthoevidene.com/AceReport/Report/4450

Study Type:Meta-analysis/Systematic Review
OE Level Evidence:1
Journal Level of Evidence:N/A

Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons

BMJ. 2012 Jun 14;344:e3675. doi: 10.1136/bmj.e3675

Contributing Authors: A Gomez-Outes AI Terleira-Fernandez ML Suarez-Gea E Vargas-Castrillon

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here


A meta-analysis of 16 randomized trials (38747 patients) was conducted to investigate the effects of new oral anticoagulants (rivaroxaban, dabigatran, and apixaban), compared with standard enoxaparin, for prophylaxis against venous thromboembolism after total hip or knee replacement surgery. After investigating relative risks of symptomatic venous thromboembolism, clinically relevant bleeding, and...

To view the full report, start your 30-day free trial today

No credit card required

JOIN Forgot Password?

Not sure if you want to join OrthoEvidence?

Access this report without an Account.

Success, an email containing a link to access this report has been sent to your inbox.

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.


Please Login or Join to leave comments.